계명대학교 의학도서관 Repository

간세포암 환자에서 Sorafenib 사용 후 발생한 한관종 유사 땀샘관 증식

Metadata Downloads
Affiliated Author(s)
김성애오병호이규석
Alternative Author(s)
Oh, Byung HoKim, Sung AeLee, Kyu Suk
Journal Title
대한피부과학회지
ISSN
0494-4739
Issued Date
2017
Keyword
SorafenibSyringomaHepatocellular carcinoma
Abstract
Syringomas are common benign neoplasms that are derived from the intradermal eccrine duct and frequently manifest in adult females as 1∼3-mm flesh-colored papules on the face, especially on the lower eyelid. There are two hypotheses about their pathogenesis: ductal obstruction by keratin plugs and reactive eccrine proliferation following an inflammatory condition. The patient was a 66-year-old man with multiple erythematous papules and nodules on both periorbital areas after 7-day sorafenib (Nexavarⓡ) treatment. A skin biopsy of the Rt. periorbital lesion revealed multiple cysts and tadpole-shaped tubular structures in the dermal layer. Inflammatory cell infiltration was seen throughout the dermis. Based on the clinical features and histological findings, we diagnosed the patient with syringoma-like eccrine duct proliferation. The indications for and use of Sorafenib have increased recently. Although sorafenib-associated cutaneous side effects have increased, no cases of syringoma-like eccrine duct proliferation have been reported to date. Here we report a case of sorafenib-induced syringoma-like eccrine duct proliferation in a patient with hepatocellular carcinoma. (Korean J Dermatol 2017;55(4):246∼248)
Alternative Title
Sorafenib-induced Syringoma-like Eccrine Duct Proliferation in a Patient with Hepatocellular Carcinoma
Department
Dept. of Dermatology (피부과학)
Publisher
School of Medicine
Citation
이준범 et al. (2017). 간세포암 환자에서 Sorafenib 사용 후 발생한 한관종 유사 땀샘관 증식. 대한피부과학회지, 55(4), 246–248.
Type
Article
ISSN
0494-4739
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32874
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Dermatology (피부과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.